Interleukin-10 as a possible mediator of immunosuppressive effect in patients with squamous cell carcinoma of the head and neck

Annals of Surgical Oncology

Volumn 4, Issue 2, 1997, Pages 184-190

  Avradopoulos, Konstantine ^a   Mehta, S ^a   Blackinton, D ^a   Wanebo, Harold J ^a,b  

^a BROWN UNIVERSITY   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

Immunosuppression; Interleukin 10; Squamous carcinoma of head and neck

Indexed keywords

INTERLEUKIN 10; INTERLEUKIN 2; TRANSFORMING GROWTH FACTOR BETA;

ARTICLE; ENZYME LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK TUMOR; HUMAN; IMMUNOLOGICAL TOLERANCE; IMMUNOLOGY; IN VITRO STUDY; PHYSIOLOGY; SQUAMOUS CELL CARCINOMA;

CARCINOMA, SQUAMOUS CELL; ENZYME-LINKED IMMUNOSORBENT ASSAY; HEAD AND NECK NEOPLASMS; HUMANS; IMMUNE TOLERANCE; INTERLEUKIN-10; INTERLEUKIN-2; TRANSFORMING GROWTH FACTOR BETA;

EID: 0031087478     PISSN: 10689265     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02303803     Document Type: Article

References (31)

1. Wanebo HJ, Jun MY, Strong EW, et al. T cell deficiency in patients with squamous cell carcinoma of the head and neck. Am J Surg 1975;130:445-51.
2. Hilal EY, Wanebo HJ, Pinsky CM, et al. Immunologic evaluation and prognosis in patients with head and neck cancer. Am J Surg 1977;134:469-73.
3. Papenhausen PR, Kukwa A, Croft CB, et al. Cellular immunity in patients with epidermoid carcinoma of the head and neck. Laryngoscope 1979;89:538-49.
4. Schantz SP, Shillitoe EJ, Brown B, et al. Natural killer cell activity and head and neck cancer: clinical assessment. J Nail Cancer Inst 1986;77:869-75.
5. Mickel RA, Kessler DJ, Taylor MG. Natural killer cell cytotoxicity in peripheral blood, cervical lymph nodes, and tumor of head and neck cancer patients. Cancer Res 1988; 48:5017-22.
6. Wustrow TP, Zenner HP. NK cell activity in patients with carcinoma of the larynx and hypopharynx. Laryngoscope 1985;95:1391-400.
7. Bugis SP, Lotzova E, Savage HE, et al. Inhibition of LAK generation by blocking factors in sera of patients with head and neck carcinoma. Cancer Immunol Immunother 1990;31: 176-81.
8. Kumazawa H, Hess M. Influence of serum derived from patients with head and neck cancer on natural killer cell activity. Oncology 1991;48:372-6.
9. Wanebo HJ, Blackinton D, Kouttab N, et al. Contribution of serum inhibitory factors and immune cellular defects to the depressed cell-mediated immunity in patients with head and neck cancer. Am J Surg 1993;166:389-94.
10. Lapointe H, Lampe H, Banerjee D. Head and neck squamous cell carcinoma cell line-induced suppression of in vitro lymphocyte proliferative responses. Otolaryngol Head Neck Surg 1992;106:149-58.
11. Avradopoulos D, Mehta S, Blackinton D, Wanebo H. Mechanism of suppression of T-cell responses by head and neck cancer patient derived serum factors [Abstract]. Presented at the 47th Cancer Symposium, Society of Surgical Oncology, 1994.
12. Cortesina G, Sacchi M, Galeazzi E, et al. Immunology of head and neck cancer: perspectives. Head Neck 1993:10: 74-7.
13. Sporn MB, Roberts AB. Transforming growth factor betas: past, present, future. Ann N Y Acad Sci 1992;106:345-56.
14. Hirte H, Clark DA. Generation of lymphokine-activated killer cells in human ovarian carcinoma ascitic fluid: identification of transforming growth factor-beta as a suppressive factor. Cancer Immunol Immunother 1991;32:296-302.
15. Okamura K, Morimoto A, Hamaraka R. A model for tumor angiogenesis, involvement of TGF-alpha, in tube formation of human microvascular endothelial cells induced by esophageal cancer cells. Biochem Biophys Res Commun 1992:186:1471-9.
16. Ortaldo JR, Mason AT, O'Shea JJ, et al. Mechanistic studies of TGF-beta inhibition of IL-2 dependent activation of CD3 - large granular lymphocyte function. J Immunol 1991; 146:3791-8.
17. Florentino DG, Bond MW, Mosmann T. Two types of mouse T helper cells. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones. J Exp Med 1989;170: 2081-95.
18. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991;147:3444-51.
19. de Waal Malefyt R, Abrams J, Bennett B, Figdor CG, deVries JE. Interleukin 10 (IL-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med 1991;174:1209-20.
20. Uyemura K, Moy RL, Dubinett S, et al. IL-10 production in basal cell carcinoma and mechanism for evading the local immune response [Abstract]. FASEB J 1994;8:230.
21. Mosmann TR, Cherwinski H, Bond MW, Giedlin MA, Coffman RL. Two types of murine helper T cell clone. J Immunol 1986;136:2348-57.
22. Mosmann TR. Properties and functions of interleukin-10. Adv Immunol 1994;56:1-25.
23. Del Prete GF, De Carli M, Mastromauro C, et al. Purified protein derivative (PPD) of Mycobacterium tuberculosis and excretory-secretory antigens (TES) of Toxocara canis expand in vitro human T cells with stable and opposite (type 1 T helper or type 2 T helper) profiles of cytokine production. J Clin Invest 1991;88:346-50.
24. Palliard X, De Waall Malefijt R, Yssel H, et al. Simultaneous production of IL-1, IL-4, and IFN-gamma by activated human CD4+ and CD8+ T cell clones. J Immunol 1987;141: 849-55.
25. Kim J, Brannan C, Copeland NG, Jenkins NA, Khan TA, Moore KW. Structure of the mouse IL-10 gene and chromosomal localization of the mouse and human genes. J Immunol 1992;148:3618-23.
26. Goodman RE, Oblak J, Bell RG. Synthesis and characterization of rat interleukin-10 (IL-10), cDNA clones from the RNA of cultured OX8-OX22-thoracic duct T cells. Biochem Biophys Res Commun 1992;189:1-7.
27. Hsu D, de Wall Malefyt R, Fiorentino DF, et al. Expression of interleukin-10 activity by Epstein-Barr virus protein BCRF 1. Science 1990;250:830-2.
28. Moore KW, Viera P, Fiorentino DF, Trounstine ML, Khan TA, Mosmann TR. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRF1. Science 1990;248:1230-3.
29. Viera P, de Wall-Malefyt R, Dang MN, et al. Isolation and expression of human cytokine synthesis inhibitory factor cDNA clones: homology to Epstein-Barr virus open reading frame BCRFI. Proc Natl Acad Sci USA 1991;88:1172-6.
30. Rode HJ, Janssen W, Rosen-Wolff A, et al. The genome of equine herpesvirus type 2 harbors an interleukin 10 (IL-10)-like gene. Virus Genes 1993;7:111-6.
31. Oswald IP, Gazzinelli RT, Sher A, James SL. IL-10 syner-gizes with IL-4 and transforming growth factor-beta to inhibit macrophage cytotoxic activity. J Immnnol 1992;148: 3578-82.